Review: Rofecoxib increases renal events and arrhythmia, but a COX-2-inhibitor class effect does not exist

Molony, Donald A.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p25
Academic Journal
The article discusses a research study regarding the risk factors for renal and arrhythmia events in patients using cyclooxygenase-2 (COX-2) inhibitors. The study was conducted by researcher J. Zhang, and published in the "Journal of the American Medical Association." Use of rofecoxib increases risks for renal events and arrhythmia. Evidence of increased risk associated with other COX-2 inhibitors is not supported, indicating no overall class effect.


Related Articles

  • Review: Risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin, but not celecoxib. Bradley, Colin P. // ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p24 

    The article offers information on a research study regarding risk factors that lead to cardiovascular (CV) events in patients using cyclo-oxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs. The study was conducted by researcher P. McGettigan, and published in the "Journal of the...

  • New meta-analyses evaluate effect of COX-2 inhibitors on renal and CV events, including arrhythmia.  // Formulary;Nov2006, Vol. 41 Issue 11, p558 

    The article presents information on the two new meta-analyses that evaluate the adverse effects of cyclooxygenase-2 (COX-2) inhibitors on renal and cardiovascular events including arrhythmia. A population-based study was conducted by the researchers to know the effect of COX-2. One of the...

  • Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events. Jingjing Zhang; Ding, Eric L.; Yiqing Song // JAMA: Journal of the American Medical Association;10/4/2006, Vol. 296 Issue 13, p1619 

    Context Adverse effects of selective cyclooxygenase 2 (COX-2) inhibitors on renal events and arrhythmia have been controversial, with suggestions of a class effect. Objective To quantitatively evaluate adverse risks of renal events (renal dysfunction, hypertension, and peripheral edema) and...

  • JAMA wants campaign on clinical alerts. Josefson, Deborah // BMJ: British Medical Journal (International Edition);11/29/97, Vol. 315 Issue 7120, p1399 

    Reports that the `Journal of the American Medical Association' is organizing a campaign of clinical alerts to ensure that patients benefit quickly from medical breakthroughs. Campaign's means of relaying messages across the country; Evidence that medical treatments reported in the literature...

  • Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Klein, Thomas; Eltze, Manfrid; Grebe, Thomas; Hatzelmann, Armin; K�mhoff, Martin // Cardiovascular Research;Jul2007, Vol. 75 Issue 2, p390 

    Abstract: Objective : Celecoxib carries a smaller cardiovascular risk for myocardial infarction and hypertension than other cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drugs NSAIDs (�coxibs�) and may ameliorate endothelial dysfunction. We aimed to determine which...

  • The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Kawashima, Masayuki; Fujikawa, Yosuke; Itonaga, Ichiro; Takita, Chikahiro; Tsumura, Hiroshi // Modern Rheumatology (Springer Science & Business Media B.V.);Apr2009, Vol. 19 Issue 2, p192 

    The inducible prostaglandin synthesis enzyme, cyclooxygenase-2 (COX-2), is involved in bone resorption and osteoclastogenesis, and acts indirectly through prostaglandin E2 (PG E2) produced by osteoblastic cells. This study was undertaken to investigate whether celecoxib (a selective COX-2...

  • COX-2 inhibitors: 'risk-inducing' effect at higher doses.  // Reactions Weekly;10/14/2006, Issue 1123, p5 

    The article discusses research being done on the risk-reducing effect of cyclooxygenase-2 inhibitors at higher doses. According to researchers from Australia, the overall risk of acute coronary syndromes (ACS) does not appear to increase with the use of celecoxib or rofecoxib, but the odds of...

  • JAMA Addresses Conflicts of Interest. Brichacek, Andra // Pharmaceutical Executive;Dec2000, Vol. 20 Issue 12, p75 

    Deals with the move of the `Journal of the American Medical Association' to address the issue of conflicts of interest among academic researchers and contributors to the periodical. Discussion on the issue of conflict of interest when a researcher has financial stake to a pharmaceutical company;...

  • Update on JAMA's Policy on Release of Information to the Public. Fontanarosa, Phil B.; Flanagin, Annette; DeAngelis, Catherine D. // JAMA: Journal of the American Medical Association;10/1/2008, Vol. 300 Issue 13, p1585 

    The author reflects on the policies of the "Journal of the American Medical Association" (JAMA), specifically the policies regarding the publication's previously published editorials and release of information to the public. Other topics include manuscripts submitted for evaluation, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics